Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Mutant-Selective Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TP53 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Mutant Antigen Panel | TP53 Hotspot Mutant Proteins (R175H, R248Q, R273H, Y220C) Sequence Verified, High Purity (>95%), Endotoxin <1EU/µg, HEK293 Expressed |
View TP53 Products |
| Wild-Type Control | TP53 WT Full-Length Recombinant Protein DNA-Binding Domain Verified, Theoretical MW confirmed by Mass Spec |
View TP53 Products |
| E3 Ligase Target | MDM2 Protein (TP53 Binding Domain) For PPI disruption assays, SPR/ITC Ready, High Purity |
View MDM2 Products |
| Alternative Regulator | MDM4 (MDMX) Protein HEK293 Expressed, Sequence Verified, for dual inhibition studies |
View MDM4 Products |
| Gene Delivery | TP53 Promise-ORF / Lentivirus Wild-type and mutant ORF for stable reporter cell line construction |
View TP53 Products |
| Benchmark Antibody | Anti-TP53 (DO-1 Clone Sequence) Recombinant positive control for IHC/WB, Sequence Verified |
View TP53 Products |
| Functional Validator | TP53 siRNA Set For knockdown verification in p53 reporter assays |
View TP53 Products |
| Downstream Marker | CDKN1A (p21) Recombinant Protein Cell cycle arrest validation, High Purity |
View CDKN1A Products |
| Synthetic Lethal Partner | WEE1 Recombinant Protein For combination therapy screening assays |
View WEE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs WT Selectivity Screening | Hotspot Mutant Panel (R175H, R248Q, R273H, Y220C) with matched WT control; >95% purity; Endotoxin controlled |
| MDM2/MDMX PPI Disruption | Full-length MDM2 and MDM4 proteins; Native conformation for SPR/ITC; Sequence verified |
| Thermal Stability Shift (Compound Binding) | Purified mutant proteins with documented structural instability; Suitable for DSF/TSA assays |
| DNA Binding Function Restoration | WT and mutant DNA-binding domain fragments; For EMSA/FP/SPR-based DNA binding assays |
| False Positive Control | Matched siRNA and benchmark antibody (DO-1) for assay specificity verification |
Live TP53 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TP53-targeted therapeutics has shifted from non-selective approaches to mutation-specific reactivation. Following the setback of broad-acting agents, the field is pivoting toward structural mutants (e.g., Y220C) and synthetic lethal combinations. As first-generation MDM2 inhibitors face hematologic toxicity limits, the next wave of R&D focuses on mutant-selective small molecules, stapled peptides, and targeted protein degradation (PROTACs) to avoid wild-type p53 activation toxicity and expand druggable space.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Mutant-Selective Small Molecules | PMV Pharma, Aprea Therapeutics | Solid Tumors (Y220C, R175H mutations) | Thermal Shift & DNA Binding Assays (Need mutant vs WT protein panel) |
| MDM2 Inhibitors | Roche, Novartis, Daiichi Sankyo | AML, Liposarcoma, Hematological Malignancies | PPI Disruption Assays (Need full-length MDM2/MDMX proteins) |
| Stapled Peptides | Aileron Therapeutics | Advanced Solid Tumors | Cell Permeability & Stability Tests (Need mutant protein targets) |
| WEE1 Combinations | AstraZeneca, Zentalis | TP53-mutant Ovarian Cancer | Synthetic Lethal Screening (Need WEE1 + TP53 mutant proteins) |
| PROTACs | Various Biotechs | Refractory Cancers | Degradation Assay (Need stable cell lines via Lentivirus) |